MK-677 (Ibutamoren): Oral GH Secretagogue, Honestly Reviewed

MK-677, also known as ibutamoren, is an orally active growth-hormone secretagogue that raises growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Despite usually being lumped in with growth-hormone peptides, it is not a peptide: it is a non-peptide small molecule, which is why it works as a pill rather than an injection. It has more published human data than most compounds in this category, but the best long-term trial showed lean-mass gain without any improvement in strength or function, alongside higher blood glucose. It is not FDA-approved, is sold as a research chemical, and is banned in sport.

What MK-677 is, and why "not a peptide" matters

MK-677 is a small synthetic molecule that mimics ghrelin, the hormone that signals hunger, and binds the growth-hormone secretagogue receptor (GHSR-1a). Activating that receptor prompts the pituitary to release GH in pulses while also producing a more continuous elevation of IGF-1. The ghrelin mimicry is also why it stimulates appetite, which for many users is a significant and unwanted effect.

The "not a peptide" point is more than a technicality. Peptides like ipamorelin or CJC-1295 have to be injected because the digestive tract breaks peptides down. MK-677 is orally bioavailable, so it sidesteps needles entirely. That oral convenience shapes how it is marketed and used, and it puts MK-677 in a slightly different regulatory position from injectable research peptides. For the side-by-side, see ipamorelin vs MK-677.

One more mechanistic detail matters for understanding both the appeal and the downsides. MK-677 produces a pulsatile rise in GH but a more continuous elevation in IGF-1, and because it has a relatively long duration of action, a single daily dose keeps GH and IGF-1 elevated around the clock. That sustained elevation is part of why fluid retention and metabolic effects show up, and it is a meaningful difference from a short-acting injectable peptide that produces a briefer pulse. More hormone exposure for longer is not automatically better; it is also more of whatever side effects come with GH-axis stimulation.

The evidence: more human data than most, but read it carefully

Unlike many compounds in this lane, MK-677 has been studied in actual people, and the most informative trial is worth understanding in full because the marketing rarely tells the whole story.

In a 12-month, double-blind study (Nass and colleagues, 2008, published in Annals of Internal Medicine), 65 healthy older adults took 25 mg per day. The results were mixed in a telling way. Participants gained about 1.1 kg of lean mass and roughly 1.5 kg of total body weight, meaning some of the gain was fat. Critically, there was no improvement in muscle strength or functional outcomes, which were the things that would actually matter for quality of life. Fasting glucose rose by about 5 mg/dL and insulin sensitivity worsened.

So the honest read is that MK-677 reliably nudges body composition numbers but did not deliver functional benefit in the best trial we have, while it did move metabolic markers in the wrong direction. It has also been investigated in conditions like cancer cachexia and hip-fracture recovery, with some effects on body composition but mixed functional results, and it is not approved for any of these. If you are weighing it against other options for muscle, our best peptides for muscle guide ranks the evidence.

The distinction between lean mass and useful muscle is the crux, and it is easy to gloss over. "Lean body mass" on a body-composition readout includes water and other non-fat tissue, not just contractile skeletal muscle. Given that MK-677 causes fluid retention, a chunk of the lean-mass gain reported in trials and by users may be water rather than new muscle fiber, which fits neatly with the trial finding that strength did not improve. A bigger number on the scale or on a body-fat scan is not the same as being stronger or more capable, and MK-677 is a good case study in why that gap exists.

Sleep is another commonly cited reason people try MK-677, since some studies and reports describe increased slow-wave sleep, plausibly tied to the GH-axis effect. The evidence here is genuinely mixed and modest, and the appetite increase that comes bundled with it can undercut anyone using the compound for fat loss. As with the muscle claims, a subjective benefit like "I slept better" is worth tracking honestly rather than assuming, because expectation effects are powerful.

Common reported uses, and the off-label reality

MK-677 is promoted for muscle gain, recovery, fat loss, improved sleep, and anti-aging "GH optimization." None of these is an approved use, because MK-677 has no FDA-approved indication at all. The bodybuilding community's enthusiasm runs well ahead of the trial evidence, which, as above, showed lean-mass changes without strength or function gains. Treat the recomposition claims as unproven, and remember that GH-axis manipulation is not a substitute for training and protein. Our GH peptides for body recomposition piece covers that hype-versus-evidence gap across the whole class.

Side effects: oral does not mean harmless

The side-effect profile is the part that the "just take a pill" framing tends to bury. Commonly reported effects include:

• Increased appetite. A direct result of the ghrelin mimicry, and a problem if your goal is fat loss.
• Water retention and edema. Often noticeable, and part of why early scale changes can overstate real tissue gain.
• Lethargy. Reported by some users, sometimes pronounced.
• Raised fasting glucose and reduced insulin sensitivity. Documented in the 12-month trial, and the most clinically meaningful concern, especially for anyone with prediabetes or diabetes.

There are also the broader GH-axis class concerns shared across these compounds: the theoretical worry that raising IGF-1 could stimulate a pre-existing malignancy, and the general caution that long-term safety in healthy people is not established. Because MK-677 raises appetite and can add fat, the weight changes it produces are not automatically good news, which is exactly why watching fat-versus-lean trends matters more than watching the scale. If you are also on a GLP-1 and worried about losing muscle, our signs you are losing muscle guide explains the warning signs.

Regulatory status: not approved, gray-market, and banned in sport

MK-677 is not FDA-approved for any indication. It retains investigational-drug status from prior research but has never been approved. The FDA has explicitly warned that it is not legal as a dietary supplement ingredient, and products containing ibutamoren have turned up among adulterated supplements, which is a real consumer-safety problem because buyers may not know what they are taking.

In practice, it is sold in the US as a "research chemical," a legal gray zone with no quality oversight, so purity and dosing accuracy are not guaranteed. For sport, MK-677 is on the WADA Prohibited List under category S2 as a GH secretagogue, banned at all times, in and out of competition. If you are tested, this is a sanction risk. For the broader legal landscape, see our overview of whether peptides are legal in 2026, and check FDA.gov for the current picture, since this is evolving.

Who should be especially cautious

A few groups have particular reason to steer clear of MK-677 without close clinical oversight, and they are worth naming because the oral, supplement-adjacent marketing can make it feel low-stakes.

Anyone with prediabetes, type 2 diabetes, or a strong family history of metabolic disease should weigh the documented glucose and insulin-sensitivity effects heavily, since a compound that worsens those markers is working against them. People with a personal or family history of cancer have the IGF-1 concern to consider, because raising IGF-1 is theoretically capable of supporting the growth of existing malignant cells. Those with heart failure or fluid-balance issues should factor in the water retention. And competitive athletes in any tested sport face a clear ban, with no therapeutic-use carve-out for physique or performance goals.

None of this means MK-677 is uniquely dangerous; it means the "just a pill" framing understates a real side-effect and risk profile. The convenience is genuine, but convenience is not the same as safety, and the people most drawn to it for body composition are sometimes the ones with the most to lose from its metabolic effects.

What to ask a provider

If you are discussing MK-677 with a licensed clinician, useful questions include: What does the actual human trial data show for my goal, and does it show functional benefit? How would we monitor fasting glucose and insulin sensitivity? Do I have metabolic, cardiovascular, or malignancy risk factors that argue against it? And is there a better-supported path to the same goal? A clinician is accountable for your care in a way no forum or article can be.

The tracking angle

MK-677's signature effects, appetite and water retention, both show up loudly in body-weight data and can easily mask what is really happening to your fat and muscle. Myo separates fat-versus-lean trends and logs side effects, so you and your provider can read what is actually changing instead of trusting a number on the scale that may be water and food weight.

Because MK-677 is oral, the logging job is simpler than with injectables, but no less useful: dose timing, appetite, sleep, energy, and any glucose readings your clinician asks you to take all become a trend you can review together. That turns "I think it is working" into data, and it pairs naturally with the same fat-versus-muscle tracking Myo was built around for GLP-1 muscle loss. The tool tracks a provider-directed protocol; it does not recommend or source anything.

References

• Nass R, et al. Effects of an oral ghrelin mimetic (MK-677) on body composition and physical performance in healthy older adults: a 12-month randomized controlled trial. Ann Intern Med (2008).
• US FDA. Warnings that ibutamoren (MK-677) is not a lawful dietary supplement ingredient; adulterated-product findings. FDA.gov.
• Operation Supplement Safety (OPSS). Ibutamoren (MK-677) information for service members. opss.org.
• World Anti-Doping Agency. 2026 Prohibited List, category S2 (GH secretagogues and mimetics). wada-ama.org.